Skip to content

Janux Therapeutics, Inc.

JANX

CIK 0001817713

← back to feed
Revenue (TTM)
$13.73M
−5.6% YoY Q1 May 2026
Net Income (TTM)
−$106.04M
−64.7% YoY Q1 May 2026
EPS Diluted (TTM)
−$1.71
−43.0% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
-1,088.5%
Q1 May 2026
Net Margin
-772.2%
Q1 May 2026
Free Cash Flow (TTM)
−$59.24M
Q1 May 2026
Cash
$51.83M
Q1 May 2026
Total Debt
—
Q1 May 2026
Shares Outstanding
60.98M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings